{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In a first group of embodiments, the invention provides methods for modulating a biological activity of a target cell using a bispecific binding agent (i) having a first binding domain having a Kd for a first target molecule on the surface of said cell of 10<sup>\u22127 </sup>M or less and a second binding domain having a Kd for a second target molecule on the surface of said cell, \n* In some embodiments, the Kd of the first binding domain to the first target molecule is between 10<sup>\u22128 </sup>and 10<sup>\u221212 </sup>M.\n* In some embodiments, the Kd of the second binding domain to the second target molecule is at least 20 times greater than the Kd of the first binding domain to the first target molecule.\n* In some embodiments, the Kd of the second binding domain is more than 50 times greater than the Kd of the first binding domain.\n* In some embodiments, the Kd of the second binding domain is 100 or more times greater than the Kd of the first binding domain.\n* The invention further provides methods for modulating biological activity of a target molecule on a target cell in an organism having target and non-target cells, wherein the target cells have a first target molecule on their exterior and a second target molecule on their exterior surface, and wherein (i) the first and second target molecules do not share a common ligand, (ii) the first target molecule is at least 10 times more abundant on the surface of the target cells than on non-target cells that also bear the second target molecule, (iii) the second target molecule has a biological activity, but the first target molecule does not, and (iv) when the target molecule of the first binding domain is ErbB2 (HER2), the target molecule for the second binding domain is not ErbB3 (HER3), comprising using a bispecific binding agent having a first binding domain having a dissociation constant (Kd) for the first target molecule of 10<sup>\u22127 </sup>M or less and a second binding domain having a Kd for the second target molecule that is at least 10 times greater than the Kd of the first binding domain, \n* In some embodiments, the Kd of the first binding domain for the first target molecule is between 10<sup>\u22128 </sup>M and 10<sup>\u221212 </sup>M.\n* In some embodiments, the Kd of the second binding domain to the second target molecule is at least 20 times greater than the Kd of the first binding domain to the first target molecule.\n* In some embodiments, the Kd of the second binding domain to the second target molecule is at least 50 times greater than the Kd of the first binding domain to the first target molecule.\n* In another group of embodiments, the invention provides bispecific binding agents (bsBAs) comprising a first binding domain having a dissociation constant (Kd) of 10<sup>\u22127 </sup>M or less for a first target molecule on a target cell and a second binding domain having a Kd for a second target molecule on a target cell which Kd is at least 10 times greater than the Kd of the first binding domain for the first target molecule, \n* In some embodiments, the Kd of the second binding domain is more than 50 times greater than the Kd of the first binding domain.\n* In some embodiments, the Kd of the second binding domain is 100 or more times greater than the Kd of the first binding domain.\n* In still another group of embodiments, the invention provides compositions of (a) a bispecific binding agent (bsBA) comprising a first binding domain having a dissociation constant (Kd) for a first target molecule on a target cell of 10<sup>\u22127 </sup>M or less and a second binding domain having a Kd for a second target molecule on a target cell that is at least 10 times greater than the Kd of the first binding domain, \n* In some embodiments, the Kd of the second binding domain is more than 50 times greater than the Kd of the first binding domain.\n* In some embodiments, the Kd of the second binding domain is 100 or more times greater than the Kd of the first binding domain.\n* In another group of embodiments, the invention provides uses of a bispecific binding agent (bsBA) comprising a first binding domain having a dissociation constant (Kd) for a first target molecule on a target cell of 10<sup>\u22127 </sup>M or less and a second binding domain having a Kd for a second target molecule on a target cell that is at least 10 times greater than the Kd of the first binding domain, \n* In some embodiments, the Kd of said second binding domain is more than 50 times greater than the Kd of the first binding domain.\n* In some embodiments, the Kd of said second binding domain is 100 or more times greater than the Kd of the first binding domain.\n* Further, the invention provides kits comprising (a) a container, and (b) a bispecific binding agent (bsBA) comprising a first binding domain having a dissociation constant (Kd) of 10<sup>\u22127 </sup>M or less for a first target molecule on a target cell and a second binding domain having a Kd for a second target molecule on a target cell which Kd is at least 10 times greater than the Kd of the first binding domain for the first target molecule, \n* In some embodiments, the Kd of the second binding domain is more than 50 times greater than the Kd of the first binding domain.\n* In some embodiments, the Kd of the second binding domain is 100 or more times greater than the Kd of the first binding domain.\n* In some embodiments, the Kd of the first binding domain is between 10<sup>\u22128 </sup>and 10<sup>\u221212 </sup>M."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-7}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-8} to 10^{-12}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-7}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-8} to 10^{-12}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-7}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-7}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-8} to 10^{-12}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-7}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-7}", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10^{-8} to 10^{-12}", "unit": "M", "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or other identifiers along with bioactivity metrics, numeric values, and units."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe dissociation constant of the targeting domain for its target molecule is in the range of 10<sup>\u22128 </sup>to 10<sup>\u221212 </sup>M."}
{"final_json": [{"molecule_name": null, "protein_target_name": "targeting domain", "binding_metric": "Kd", "value": "10\u22128 to 10\u221212", "unit": "M", "is_logarithmic": false}]}
{"raw_mentions": "A univalent binding agent will therefore typically still have a Kd in the nanomolar range. \nPersons of skill will recognize that an antibody with a Kd of 10\u22128 M has an affinity 10 times as high as one with a Kd of 10\u22127, and 100 times the affinity of an antibody with a Kd of 10\u22126."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10\u22128", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10\u22127", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "10\u22126", "unit": "M", "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or other identifiers along with bioactivity metrics, numeric values, and units. The text primarily discusses methods and general concepts related to bsBAs and their applications, without providing specific data that includes all four required components."}
{"raw_mentions": "The Kd of VEGF binding to VEGFR1 and VEGFR2 is 15-100 \u03bcM and 400-800 \u03bcM, respectively (Terman et al., 1994)."}
{"final_json": [{"molecule_name": "VEGF", "protein_target_name": "VEGFR1", "binding_metric": "Kd", "value": "15-100", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "VEGF", "protein_target_name": "VEGFR2", "binding_metric": "Kd", "value": "400-800", "unit": "\u03bcM", "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or identifiers along with bioactivity metrics, numeric values, and units. The text primarily describes methods and procedures for testing and measuring binding domains and effector functions."}
{"raw_mentions": "Based on our in silico analysis of the ErbB cell signaling pathway, we identified the ErbB 1 binding molecule as the high affinity binding site with a low dissociation constant KD<1 nM, but which is not irreversible."}
{"final_json": [{"molecule_name": "ErbB 1 binding molecule", "protein_target_name": "ErbB", "binding_metric": "KD", "value": "<1", "unit": "nM", "is_logarithmic": false}]}
